FDA Approves World's First Respiratory Syncytial Virus Vaccine for Adults Aged 60 and Older

According to CCTV News, on May 3 local time, the U.S. Food and Drug Administration (FDA) approved the vaccination of people aged 60 and above with GlaxoSmithKline (GSK)'s respiratory syncytial virus (RSV) vaccine "Arexvy". According to a report by CNN, this is the world's first approved RSV vaccine after 60 years of research.